Evidence map›Paper›PMID 29415603›Full record

ArticleLeukemia & lymphoma2018

A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.

Fiona He, Smarika Sapkota, Sarah Parker, Todd Defor, Erica Warlick, Celalettin Ustun, Craig Eckfeldt, Armin Rashidi, Andy Kurtzweil, Daniel Weisdorf and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Fiona Hea Division of Hematology, Oncology and Transplantation, Department of Medicine , University of Minnesota , Minneapolis , MN , USA.ORCID 0000-0003-0782-1170
Smarika Sapkotab Division of General Internal Medicine, Department of Medicine , University of Minnesota , Minneapolis , MN , USA.
Sarah Parkerb Division of General Internal Medicine, Department of Medicine , University of Minnesota , Minneapolis , MN , USA.
Todd Deforc Biostatistics and Bioinformatics Core, Masonic Cancer Center , University of Minnesota , Minneapolis , MN , USA.
Erica Warlicka Division of Hematology, Oncology and Transplantation, Department of Medicine , University of Minnesota , Minneapolis , MN , USA.
Celalettin Ustuna Division of Hematology, Oncology and Transplantation, Department of Medicine , University of Minnesota , Minneapolis , MN , USA.
Craig Eckfeldta Division of Hematology, Oncology and Transplantation, Department of Medicine , University of Minnesota , Minneapolis , MN , USA.ORCID 0000-0003-2834-0421
Armin Rashidia Division of Hematology, Oncology and Transplantation, Department of Medicine , University of Minnesota , Minneapolis , MN , USA.
Andy Kurtzweild Department of Pharmacy , University of Minnesota Medical Center , Minneapolis , MN , USA.
Daniel Weisdorfa Division of Hematology, Oncology and Transplantation, Department of Medicine , University of Minnesota , Minneapolis , MN , USA.
Nelli Bejanyana Division of Hematology, Oncology and Transplantation, Department of Medicine , University of Minnesota , Minneapolis , MN , USA.
University of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NCATS NIH HHS UL1 TR002494
6 · The paper itself

Abstract

Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of acute myeloid leukemia (AML). We retrospectively analyzed clinical outcomes of 71 AML patients receiving Clo + Ara-C regimens at the University of Minnesota from 2011 to 2016: 44 patients (62%) had newly diagnosed AML and 27 patients (38%) had relapsed/refractory AML. The median age of patients was 69 years (interquartile range [IQR], 63-75 years). Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics. Objective response rate (ORR) was 42% in all patients with complete remission (CR) rate of 20%. Progression-free survival (PFS) at 2 years was 16% (95% CI 8-27%) and overall survival (OS) at 2 years was 21% (95% CI 11-33%) for all patients. The 30-day mortality rate was 18%. Clo + Ara-C- containing regimens are an acceptable upfront therapy option for patients who are not candidates for "7 + 3" induction, but do not induce durable remissions.

Indexed as

AgedAge FactorsAntineoplastic Combined Chemotherapy ProtocolsClofarabineCytarabineDrug Administration ScheduleFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMinnesotaProgression-Free SurvivalRemission InductionRetrospective StudiesSalvage TherapyClofarabineCytarabineacute myeloid leukemiaAra-cchemotherapeutic approachesClofarabinecytarabinemyeloid leukemias and dysplasias

Identifiers

PMID29415603
PMCPMC6839888
OpenAlexW2791064642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.